| scholarly article | Q13442814 |
| P50 | author | Roberto Cauda | Q56383721 |
| Antonio Cassone | Q89184800 | ||
| P2093 | author name string | Andrea Savarino | |
| Isabella Donatelli | |||
| Livia Di Trani | |||
| P2860 | cites work | Chloroquine is a potent inhibitor of SARS coronavirus infection and spread | Q24815979 |
| Development and validation of a genetic algorithm for flexible docking | Q28236574 | ||
| Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines | Q28255917 | ||
| Effects of chloroquine on viral infections: an old drug against today's diseases? | Q33973620 | ||
| Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms | Q33988233 | ||
| Antihistaminics, local anesthetics, and other amines as antiviral agents | Q35379653 | ||
| Avian influenza and sialic acid receptors: more than meets the eye? | Q40438112 | ||
| Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. | Q40568140 | ||
| Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks | Q41912825 | ||
| In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine | Q41913526 | ||
| Mechanism of uncoating of influenza B virus in MDCK cells: action of chloroquine | Q41921414 | ||
| Low cost anti-retroviral options: chloroquine based ARV regimen combined with hydroxyurea and lamivudine: a new economical triple therapy. | Q43554670 | ||
| Characterization of H5N2 influenza viruses from Italian poultry | Q48381683 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chloroquine | Q422438 |
| antiviral drug | Q846227 | ||
| P304 | page(s) | 67-69 | |
| P577 | publication date | 2006-02-01 | |
| P1433 | published in | Lancet Infectious Diseases | Q15724248 |
| P1476 | title | New insights into the antiviral effects of chloroquine | |
| P478 | volume | 6 |
| Q39769697 | A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells |
| Q99240141 | A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges |
| Q104492586 | A retrospective comparison of drugs against COVID-19 |
| Q33244705 | A sensitive one-step real-time PCR for detection of avian influenza viruses using a MGB probe and an internal positive control |
| Q34428880 | Activation of the unfolded protein response and autophagy after hepatitis C virus infection suppresses innate antiviral immunity in vitro |
| Q97882663 | Advances and challenges in the prevention and treatment of COVID-19 |
| Q94571389 | An Update on Current Therapeutic Drugs Treating COVID-19 |
| Q52652259 | Antiviral Activity of Novel Quinoline Derivatives against Dengue Virus Serotype 2. |
| Q38291146 | Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action? |
| Q41936262 | Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against Chikungunya virus in vero cells |
| Q40076684 | BK Virus replication in vitro: limited effect of drugs interfering with viral uptake and intracellular transport |
| Q90602641 | COVID-19 infection and rheumatoid arthritis: Faraway, so close! |
| Q94596745 | COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus |
| Q96030752 | COVID-19: Transmission, Prevention, and Potential Therapeutic Opportunities |
| Q93188504 | Can Nanotechnology and Materials Science Help the Fight against SARS-CoV-2? |
| Q92038828 | Can post-exposure prophylaxis for COVID-19 be considered as one of outbreak response strategies in long-term care hospitals? |
| Q94491475 | Candidate drugs against SARS-CoV-2 and COVID-19 |
| Q91823733 | Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society |
| Q41933000 | Chikungunya disease and chloroquine treatment |
| Q38107673 | Chikungunya virus: an update on antiviral development and challenges |
| Q24291001 | Chikungunya, an epidemic arbovirosis |
| Q98613192 | Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review |
| Q87949688 | Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 |
| Q94561886 | Chloroquine and hydroxychloroquine in the context of COVID-19 |
| Q28066142 | Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity |
| Q38906060 | Chloroquine enhances replication of influenza A virus A/WSN/33 (H1N1) in dose-, time-, and MOI-dependent manners in human lung epithelial cells A549. |
| Q86911130 | Chloroquine for the 2019 novel coronavirus SARS-CoV-2 |
| Q37087650 | Chloroquine is effective against influenza A virus in vitro but not in vivo |
| Q30513775 | Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy |
| Q37674854 | Chloroquine use improves dengue-related symptoms |
| Q96018078 | Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review |
| Q28276884 | Confronting an influenza pandemic with inexpensive generic agents: can it be done? |
| Q94539921 | Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis |
| Q90705116 | Controversial treatments: An updated understanding of the coronavirus disease 2019 |
| Q92076061 | Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children |
| Q94556027 | Covid-19 and drug therapy, what we learned |
| Q95269048 | Current Scenario of COVID-19 in Pediatric Age Group and Physiology of Immune and Thymus response |
| Q93223160 | Current status of potential therapeutic candidates for the COVID-19 crisis |
| Q94491965 | Current targeted therapeutics against COVID-19: Based on first-line experience in China |
| Q96034123 | Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment |
| Q102214659 | Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19 |
| Q39964308 | Development and in vitro evaluation of chloroquine gels as microbicides against HIV-1 infection |
| Q40137530 | Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses |
| Q34053482 | Direct, catalytic, and regioselective synthesis of 2-alkyl-, aryl-, and alkenyl-substituted N-heterocycles from N-oxides. |
| Q95283545 | Fact Versus Science Fiction: Fighting Coronavirus Disease 2019 Requires the Wisdom to Know the Difference |
| Q39062828 | Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients |
| Q97646016 | Hydroxychloroquine in Dermatology and Beyond: Recent Update |
| Q37854742 | Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy |
| Q97650827 | Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates |
| Q90482548 | Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro |
| Q60921203 | Improving Encapsulation of Hydrophilic Chloroquine Diphosphate into Biodegradable Nanoparticles: A Promising Approach against Herpes Virus Simplex-1 Infection |
| Q97594944 | Insights in chloroquine action: perspectives and implications in Malaria and COVID-19 |
| Q99624086 | Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2 |
| Q96641777 | Literature-based review of the drugs used for the treatment of COVID-19 |
| Q41911830 | Low concentration of chloroquine enhanced efficacy of cisplatin in the treatment of human ovarian cancer dependent on autophagy |
| Q36343593 | Low prevalence of Pneumocystis pneumonia in hospitalized patients with systemic lupus erythematosus: review of a clinical data warehouse |
| Q98465740 | Mechanisms Underlying Potential Therapeutic Approaches for COVID-19 |
| Q24647304 | Methamphetamine inhibits antigen processing, presentation, and phagocytosis |
| Q34530512 | Multiple virtual screening approaches for finding new hepatitis C virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitors |
| Q98775697 | NSafety and Effectiveness of Azithromycin in Patients with COVID-19: an open-label randomized trial |
| Q98157481 | Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19 |
| Q96647455 | New Insights of Emerging SARS-CoV-2: Epidemiology, Etiology, Clinical Features, Clinical Treatment, and Prevention |
| Q34007922 | New concepts in antimalarial use and mode of action in dermatology |
| Q97567828 | New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis |
| Q92047788 | Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment |
| Q94672941 | Novel coronavirus (COVID-19) infection: What a doctor on the frontline needs to know |
| Q40051547 | Obatoclax Inhibits Alphavirus Membrane Fusion by Neutralizing the Acidic Environment of Endocytic Compartments |
| Q43973239 | On the use of chloroquine for chikungunya. |
| Q96302226 | Outbreak of SARS-CoV2: Pathogenesis of infection and cardiovascular involvement |
| Q54207858 | Paradoxical Effect of Chloroquine Treatment in Enhancing Chikungunya Virus Infection. |
| Q57202110 | Pathobiology of virus glycosylation: implications to disease and prospects for treatment |
| Q99550098 | Pathophysiology and treatment strategies for COVID-19 |
| Q96124554 | Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements |
| Q57202107 | Protein glycosylation in infectious disease pathobiology and treatment |
| Q36880738 | Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century |
| Q34296062 | Reduction of immune activation with chloroquine therapy during chronic HIV infection |
| Q84360011 | Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro |
| Q34042046 | Replication cycle of chikungunya: a re-emerging arbovirus |
| Q34618922 | Retrospective survey of Chikungunya disease in Réunion Island hospital staff |
| Q95627597 | Review of trials currently testing treatment and prevention of COVID-19 |
| Q48408390 | Risks and benefits of chloroquine use in anticancer strategies |
| Q90744884 | SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat |
| Q38975509 | Signaling of chloroquine-induced stress in the yeast Saccharomyces cerevisiae requires the Hog1 and Slt2 mitogen-activated protein kinase pathways. |
| Q91598465 | Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection |
| Q40122517 | Synthesis and in vitro cytotoxicity evaluation of 4-aminoquinoline derivatives |
| Q39360987 | Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases |
| Q90744915 | Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19 |
| Q95611618 | The SARS-CoV-2 cytopathic effect is blocked with autophagy modulators |
| Q38559764 | The enigma of the clandestine association between chloroquine and HIV-1 infection |
| Q100430432 | The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies |
| Q90712071 | Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future |
| Q94590927 | Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review |
| Q47557905 | To Zika and destroy: an antimalarial drug protects fetuses from Zika infection |
| Q90744904 | Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective |
| Q36775963 | Virus glycosylation: role in virulence and immune interactions |
| Q99419033 | What are the drugs having potential against COVID-19? |
| Q107473206 | What makes (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology |
Search more.